Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
TUSTIN, Calif., Dec. 03, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the second quarter of fiscal year 2016 ended October 31, 2015 on December 10, 2015 after market and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Peregrine's senior management will discuss financial results for the second quarter and review the recent progress of its clinical development programs.
To listen to the live webcast, or access the archived webcast, please visit: http://ir.peregrineinc.com/events.cfm.
To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials focused on the treatment of cancer. The company's lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of previously treated non-small cell lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. For more information, please visit www.peregrineinc.com.
Contacts: Jay Carlson Peregrine Pharmaceuticals, Inc. (800) 987-8256 [email protected] Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 [email protected] Tim Brons (Media) Vida Strategic Partners 415-675-7402 [email protected]
